<DOC>
	<DOCNO>NCT02128542</DOCNO>
	<brief_summary>This study examine safety , tolerability , antiviral efficacy sofosbuvir ( SOF ) +ribavirin ( RBV ) treatment-naive treatment-experienced United States Veterans compensate cirrhosis genotype 2 HCV infection .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir+Ribavirin Genotype 2 HCV-infected U.S. Veterans With Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent . Treatmentnaive treatmentexperienced adult , U.S . Veteran Chronic genotype 2 ( GT2 ) HCV infection Classified : Eligible treatment interferon ( IFN ) base therapy Ineligible IFN treatment Intolerant IFN . Cirrhosis determination Laboratory parameter within prespecified range screen : A negative serum pregnancy test require female childbearing potential Males female childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Lactating female must agree discontinue nursing study drug administer . Males must agree refrain sperm donation date screen least 7 month last dose RBV , 90 day last dose study drug take RBV . Must able comply dose instruction study drug administration able complete study schedule assessment . Must generally good health determine Investigator . Current participation interventional clinical trial . Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) . History clinically significant chronic liver disease ( e.g. , hemochromatosis ; Wilson 's disease ; Î±1antitrypsin deficiency ) , except nonalcoholic steatohepatitis ( NASH ) . Decompensated liver History hemoglobinopathy Contraindication hypersensitivity RBV History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere participation full duration study , best interest individual participate . Clinically significant ECG abnormality screen . History solid organ transplantation . Presence hepatocellular carcinoma ( HCC ) Malignancy within 5 year prior screen , exception specific cancer entirely cure surgical resection ( basal cell skin cancer prostate cancer remission ) . Individuals evaluation possible malignancy eligible . Prior treatment NS5B polymerase inhibitor . Chronic use systemic immunosuppressive agent immunomodulatory agent ( e.g. , prednisone equivalent &gt; 10 mg/day ) . Concomitant disallow per Sovaldi Packet Insert . Known hypersensitivity study drug , metabolite , formulation excipient . History difficulty blood collection and/or poor venous access purpose phlebotomy . Use prohibit concomitant medication describe study protocol Gastrointestinal disorder postoperative condition could interfere absorption study drug . Male pregnant female partner . In judgment investigator clinicallyrelevant drug alcohol abuse within 12 month screen may interfere treatment , assessment compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Veterans HCV</keyword>
</DOC>